A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

What is the purpose of this trial?

The purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of NHS-IL12 when given in combination with a fixed avelumab dose in subjects with metastatic or locally advanced solid tumors.

EMD Serono, Inc.

Start Date: 08/11/2017

End Date: 12/01/2018

Last Updated: 02/22/2018

Study HIC#: 2000020301

Get Involved

For more information about this study, contact:
Karen Forman
+1 203-671-0783

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Mario Sznol

Principal Investigator